CERS at a glance
CERUS CORP (CERS, SEC CIK 1020214) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on July 30, 2026, an 8-K current report on July 30, 2026 and Form 4 insider filings as recently as August 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), CERUS CORP (CERS) reported revenue of $233.8 million (up 16.1% from FY2024) and a net loss of $15.6 million. Diluted EPS was -$0.08.
- As of June 30, 2026, 27 institutional investment managers tracked by SignalX reported holding CERUS CORP (CERS) shares worth $234.7 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Jensen Chrystal on August 17, 2026 of 30,000 shares at $2.98 per share.
- In the last 90 days, CERS insiders reported 0 open-market purchases ($0) and 2 open-market sales ($142K) on Form 4, a net sale of $142K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $233.8M
- +16.1% vs prior year
- Insiders · 90 days
- 0 buys · 2 sells
- Net −$142K
- 13F holders
- 27 funds
- $234.7M · +1 vs prior quarter
- Latest 8-K
- Jul 30, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- IFC kit sales accelerating, shifting toward blood-center customers
- BARDA agreements extended through March 2027 and September 2031
- RedeS trial completion anticipated second half of 2026; additional clinical data required before PMA discussions
Risk Factors
- Newly triggered risk: U.S. platelet shortages may reduce INTERCEPT adoption as hospitals prioritize product availability over pathogen-reduction preferences
- Regulatory risk: FDA has not granted a seven-day storage claim for INTERCEPT-treated platelets, potentially driving customers toward competing solutions
- Operational risk: Mishandling after treatment has introduced environmental bacteria, requiring heightened blood-center handling controls
- Market concentration risk: American Red Cross represents the largest U.S. blood-collection share and currently cannot produce IFC for its own accounts
- Financial risk: BARDA funding reductions, delays, or milestone disputes could significantly reduce government-contract revenue and cash flows
AI summary of the CERS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Item 2.02 filing covers fiscal year 2026 results, with substantive financial details contained in the accompanying exhibit
- Earnings information designated furnished rather than filed, limiting liability under Securities Exchange Act Section 18 and Securities Act Sections 11 and 12(a)(2)
Item EX-99.1: Item EX-99.1
- Q2 product revenue $57.4M, up 10% YoY; total revenue $63.3M, up 5%, despite government contract revenue declining 24%
- IFC demand increased approximately 20%; U.S. IFC sales reached $6.7M, up from $5.6M
Item 5.02: Departure/Appointment of Directors or Principal Officers
- William Greenman transitioned from CEO to Executive Chairman effective July 1, 2026, reducing his operating role while preserving board leadership
- Executive Chairman term runs through May 31, 2027, unless ended or extended earlier by agreement
Item 1.01: Entry into a Material Definitive Agreement
- Filing contains only the signature block, not substantive Item 1.01 agreement terms
- No deal value, counterparty, obligations, or strategic implications available from the provided text
AI summaries of CERS 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CERS
Don't miss the next CERS filing
- Alerts as it files. A push when CERS files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut CERS, by share count.
- Ask anything. An AI agent that reads every CERS filing and answers with sources.
CERS alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Jensen Chrystal | Sell | Aug 17, 2026 | 30,000 | $2.98 |
| Jayaraman Vivek K | Sell | Jul 16, 2026 | 16,666 | $3.16 |
| Jayaraman Vivek K | A | Jul 1, 2026 | 369,686 | - |
| Jayaraman Vivek K | A | Jul 1, 2026 | 554,529 | - |
| Green Kevin Dennis | Sell | Jun 30, 2026 | 33,676 | $2.94 |
| Green Kevin Dennis | A | Jun 30, 2026 | 63,600 | - |
| Jayaraman Vivek K | Sell | Jun 30, 2026 | 42,359 | $2.94 |
| Jensen Chrystal | Sell | Jun 30, 2026 | 24,329 | $2.94 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $201.3M | $233.8M |
| Operating Income | - | -$14.2M | -$8.7M |
| Net Income | -$37.5M | -$20.9M | -$15.6M |
| Op. Margin | - | -7.1% | -3.7% |
| Net Margin | - | -10.4% | -6.7% |
| Balance Sheet | |||
| Total Assets | - | $200.9M | $221.9M |
| Equity | $52.6M | $56.1M | $64.2M |
| ROE | -71.2% | -37.3% | -24.3% |
| Per Share | |||
| EPS | - | $-0.11 | $-0.08 |
| Cash Flow | |||
| Operating CF | -$43.2M | $11.4M | $4.8M |
| CapEx | $4.6M | $2.8M | $3.7M |
Source: XBRL data in CERUS CORP (CERS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate CERS share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 27 | $234.7M |
| Q1 2026 | 26 | $135.1M |
| Q4 2025 | 25 | $155.3M |
| Q3 2025 | 25 | $121.5M |
| Q2 2025 | 25 | $106.7M |
| Q1 2025 | 25 | $80.6M |
| Q4 2024 | 20 | $73.6M |
| Q3 2024 | 15 | $55.5M |
- D.E. Shaw & Co+1.75M (+47%)
- Vanguard Portfolio Management LLC+849.9K (+44%)
- Franklin Resources+750.7K (+505%)
- Two Sigma Investments+739.6K (+27%)
- Ameriprise Financial+705.5K (+155%)
- ARK Investment Management−1.23M (-6%)
- Goldman Sachs Group−450.8K (-16%)
- Bank of America Corp−349.9K (-29%)
- Millennium Management−321.7K (-75%)
- AQR Capital Management−235.0K (-11%)
- Citadel Advisors LLC+736.7K
Source: 13F-HR filings on SEC EDGAR (aggregated from 188 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CERS filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Aug 17, 2026 | - | - | - |
| 8-K | Jul 30, 2026 | - | Analysis | - |
| 10-Q | Jul 30, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 20, 2026 | - | - | - |
| 8-K | Jul 10, 2026 | - | Analysis | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 8-K | Jun 8, 2026 | - | Analysis | |
| 8-K | Jun 3, 2026 | - | Analysis | |
| 4 | Jun 2, 2026 | - | - | |
| 4 | Jun 2, 2026 | - | - | |
| 4 | Jun 2, 2026 | - | - | |
| 4 | Jun 2, 2026 | - | - | |
| 4 | Jun 2, 2026 | - | - | |
| 4 | Jun 2, 2026 | - | - | |
| 4 | Jun 2, 2026 | - | - | |
| 4 | May 5, 2026 | - | - | - |
| 10-Q | Apr 30, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Apr 30, 2026 | - | Analysis | - |
| 8-K | Apr 21, 2026 | - | Analysis | - |
| 4 | Apr 3, 2026 | - | - | - |
| 4 | Apr 3, 2026 | - | - | - |
| SC 13G | Mar 24, 2026 | - | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
CERS SEC filings: frequently asked questions
Are CERS insiders buying or selling?
In the last 90 days, CERUS CORP (CERS) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $142,194 by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold CERS stock?
As of June 30, 2026, the largest CERUS CORP (CERS) holders among the 13F filers tracked by SignalX were BlackRock ($64.9 million), ARK Investment Management ($52.4 million), Vanguard Capital Management LLC ($25.0 million), D.E. Shaw & Co ($16.0 million), State Street Corp ($13.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was CERS's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), CERUS CORP (CERS) reported revenue of $233.8 million (up 16.1% from FY2024) and a net loss of $15.6 million. Diluted EPS was -$0.08. The figures come from the XBRL data in the 10-K.
What did CERS report in its latest 8-K?
CERUS CORP (CERS) filed an 8-K on July 30, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Item 2.02 filing covers fiscal year 2026 results, with substantive financial details contained in the accompanying exhibit.
What are the latest CERS SEC filings?
CERUS CORP (CERS) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on July 30, 2026, an 8-K current report on July 30, 2026 and a Form 4 insider filing on August 17, 2026.
What is CERS's SEC CIK number?
CERUS CORP (CERS)'s SEC Central Index Key (CIK) is 1020214. EDGAR lists every CERS filing under that number.
Ask anything about CERS
The research agent reads CERS's filings, financials, insider trades and 13F holders, then answers with sources.